The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.
The SfPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients and the treatments best suited for their cancer. This is possible through research, communication, and collaboration amongst our members and with outreach to the cancer therapy community as a whole. To further the mission, we offer our members the following exclusive benefits
- SfPM members in good standing (dues paid through Dec. 31, ) are eligible for self nominations in our monthly seminars
- Exclusive access to our biannual newsletter curated by our board with articles, news and insights about the world of functional precision medicine.
- A members exclusive directory with information on research interests and home institutions to facilitate collaboration and networking
- Facilitate trainee placements in post-doc and industry settings by recognizing shared interests and partnerships
- Free registration for SfPM Annual Meetings and special conferences
- Access to recordings of our virtual meetings along with contact information of speakers to connect with
- Many more ongoing benefits
Applications for membership may be submitted at any time during the year. We look forward to having you onboard!
Virtual Monthly Seminars
Come join us for our Virtual Monthly Seminar which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series is must attend for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.
Rich Klinghoffer, PhD
“Intratumoral microdosing: Bridging the translational gap in cancer drug development and future potential as a functional diagnostic”
Berend Snijder, PhD
“Pharmacoscopy: real-time drug response testing for blood cancers and solid tumors. ”
APRIL 13, 2021
SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian Cancer
SEATTLE, April 13, 2021 -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived live tumor specimens employing its CLIA certified PARIS® Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS® Test (abstract number 534) at the American Association for Cancer Research annual meeting, taking place virtually from April 10-15, 2021.
MARCH 8, 2021
2021 Functional Precision Medicine in Blood Cancer Symposium
We cordially invite you to the 2021 Functional Precision Medicine in Blood Cancer Symposium that will be hosted in the context of a European Functional Precision Medicine Initiative in cooperation with the EHA-SWG Functional Precision Hematology, and the Society for Functional Precision Medicine. The symposium will take place March 25-26th, 2021 – virtual - and will bring together global experts on high-throughput drug screening, precision medicine and blood cancer. You’ll see familiar faces from the SfPM and more!
Please click the button below to register. To preview the schedule, please click here.
JANUARY 28, 2021
Two postdoc positions in computational cancer biology at NTNU
Are you a computational biologist or bioinformatician eager to apply your skills and ingenuity to tackle cancer? We open two postdoc researcher positions at NTNU as part of our ERA PerMed project ONCOLOGICS. The two appointed postdocs will work in close collaboration with each other and with a large research team from leading European research organizations.
OCTOBER 22, 2020
Plenary Sesion - A podcast on medicine, oncology, & health policy
Dr Anthony Letai sits down with Dr Vinay Prasad for a an episode of Plenary Session where Dr Letai speaks about precision oncology, the Match trial and NGS in cancer. Be sure to check it out!
AUGUST 17, 2020
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. Here, we utilize dynamic BH3 profiling (DBP), a functional predictive biomarker that measures net changes in mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. We employ this information to guide the use of BH3 mimetics to specifically inhibit BCL-2 pro-survival proteins, defeat resistance and avoid relapse.